Galectin Therapeutics GAAP EPS of -$0.15

1 month ago 4

Galectin Therapeutics press release (NASDAQ:GALT): Q1 GAAP EPS of -$0.15.
As of March 31, 2025, the Company had $7.4 million of cash and cash equivalents. Additionally, the Company has $11 million remaining available under two lines of credit provided by its chairman of the board to fund operations. The Company believes it has sufficient cash to fund currently planned operations and research and development activities through August 2025.

Recommended For You